Zipalertinib is named as an intervention in 4 current clinical trials in our USA and UK registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Taiho Oncology, Inc (3). The most-studied condition is Lung Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689 · ClinicalTrials.gov ↗ · Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
|
Phase 2 | Recruiting | Taiho Oncology, Inc. | UK, USA |
|
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773 · ClinicalTrials.gov ↗ · Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
|
Phase 3 | Active, closed | Taiho Oncology, Inc. | UK, USA |
|
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199 · ClinicalTrials.gov ↗ · Lung Cancer, Adjuvant, Post-surgical
|
Phase 3 | Active, closed | Taiho Oncology, Inc. | UK, USA |
|
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
NCT04036682 · Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
|
Phase 1/2 | Active, closed | Cullinan Therapeutics Inc. | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Taiho Oncology, Inc. | 3 |
| Cullinan Therapeutics Inc. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 4 | 1 |
| Clinical trials in UK | 3 | 1 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our USA and UK registers name Zipalertinib (also registered as TAS6417) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 4 trials is recruiting: 1 with sites in USA and 1 with sites in UK. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Taiho Oncology, Inc (3) and Cullinan Therapeutics Inc (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Zipalertinib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Zipalertinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Zipalertinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.